ASP3082
Phase 2Small molecule
ASP3082 is one of 8 small molecule programs targeting Advanced Non-Small Cell Lung Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Advanced Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Lorbrena
PfizerPhase 2
Surufatinib
HHutchison Medipharma Limited
Phase 2
Fabhalta
RegeneronPreclinical
Libtayo
RegeneronPreclinical
Krazati
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
ASP3082
GGustave Roussy, Cancer Campus, Grand Paris
Phase 2
NC318
NNextCure, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ASP3082. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details